Mensa Group

The group of companies that is today known as MENSA GROUP started through the establishment of PT Menjangan Sakti by its founder – Mr. Jimmy Sudharta in April 1975. The company started its business by trading pharmaceutical raw materials throughout Indonesia. With time the company expanded its business and diversified its activity to include the cosmetic, food and feed industries. Continuous growth of PT Menjangan Sakti has provided the company the ability and resources to expand into related business. Starting 1981, PT Menjangan Sakti acquired several other companies in related activity including pharmaceutical manufacturing companies and Distribution Company, forming what is today known as Mensa Group. Mensa Group comprises of several companies with diversified activity such as: - importing and trading pharmaceutical raw materials including food, feed and cosmetics; - pharmaceutical manufacturing ; - medical supplies and dental equipment manufacturing; - Pharmaceutical, hospital / medical supplies and consumer goods distribution. The group employs approximately 5000 employees, and main aim in the near future is to establish a solid synergy between the companies and amongst other to develop a nationwide distribution network as an asset for further growth.

Dexa Medica (Member of Dexa Group)

Dexa Medica has evolved from a small company established in 1969 to one of Indonesia’s largest ethical pharmaceutical companies at the beginning of the 21st century and has become a prominent, well-respected player in the domestic pharmaceutical market. Providing better health care by applying expertise was the foundation on which its founders built this Company. Honesty, trust, dedication and commitment to providing patients with the highest quality of ethical pharmaceutical products and OTC are preserved as the guiding principles, based upon which the highly professional management team and the motivated, competent staff of Dexa have developed the Company in the spirit of mutual respect, teamwork and innovation over more than four decades. Serving as a good corporate citizen is one of our responsibilities and being a strategic asset of Indonesia is one of our foremost desires. For along time Dexa has worked together with governing institutions and the Indonesian Pharmaceutical Association – championing compliance and improving the industry standards. Ir. Ferry A. Soetikno, M.Sc., M.B.A. (President Director) ------------------------ Dexa Medica is always on the lookout for talented individuals who want to grow with us. If you are interested in becoming part of our team, please visit our career site at www.dexagroupcareer.com or follow us on Instagram @dexagroupofficial. You can find information about various job opportunities, more details on how to join our team, and glimpses of life at Dexa Group!

ikaria, inc. - now a part of mallinckrodt pharmaceuticals.

Mallinckrodt is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. Areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology and pulmonology along with analgesics and central nervous system drugs for prescribing by office- and hospital-based physicians. The company's core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. The company's Specialty Brands segment includes branded medicines; its Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing; and the Global Medical Imaging segment includes contrast media and nuclear imaging agents. The company's fiscal 2014 revenue totaled $2.54 billion. To learn more about Mallinckrodt, visit www.mallinckrodt.com. Mission: Managing Complexity. Improving Lives. Values: Quality, Integrity, Service Principal Executive Office: Mallinckrodt plc Damastown Industrial Estate Mulhuddart, Dublin 15 Ireland U.S. Headquarters: 675 McDonnell Blvd. St. Louis, MO 63042 USA Website: www.mallinckrodt.com Stock Ticker: MNK Corporate Blog: http://blog.mallinckrodt.com/ Careers Website: www.mallinckrodt.com/careers Investor Relations: http://www.mallinckrodt.com/investors

Almac Group

Partnering to Advance Human Health A unique culture delivering exceptional solutions: Almac is a financially secure, privately owned organisation with 7,700+ employees globally. 600+ companies worldwide, including all the market leaders, use our services, testament itself to the quality, innovation and efficiency of our business as proven over the past 55+ years. Our vast range of services include: Biomarker Discovery & Development: Pre-clinical biomarker discovery, through to full companion diagnostic development and clinical test delivery from our CLIA lab. API Services & Chemical Development: Services for all stages of drug development for small molecules, potent and cytotoxic compounds and peptides. Pharmaceutical Development: Developing clinical candidates into an optimum formulation and manufacturing drug product for all phases of clinical trial supply. Analytical Services: Delivering comprehensive solutions supporting drug substance and product development programmes. Clinical Trial Supply: Comprehensive global clinical supply chain solutions providing physical resources and supportive technologies ensuring your clinical supply chain continually delivers across the globe. Clinical Technologies: Providing randomisation and trial supply management technology, electronic Clinical Outcome Assessments (eCOA), patient alerts and reminders, data integration and biostatistical consulting services. Commercial Services: Providing commercial manufacturing and packaging solutions and supporting commercial product launch. Find out about our exceptional career opportunities: http://www.almacgroup.com/careers and join our talent network https://www.almacgroup.com/careers/talent-network/

Ipsen

We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fueled by external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in 88 countries. For more information, visit ipsen.com. Pauta exclusiva para México: Clave de Autorización COFEPRIS: 243300201B1962 CONSULTE A SU MÉDICO.